Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

20201,445 citationsJournal Articlebronze Open Access

Authors

Sebastian Palmqvist · Lund University

Shorena Janelidze · Lund University

Yakeel T. Quiroz · Universidad de Antioquia

Henrik Zetterberg · UK Dementia Research Institute

Francisco Lopera · Universidad de Antioquia

Erik Stomrud · Skåne University Hospital

Yi Su ·

Abstract

Among 1402 participants from 3 selected cohorts, plasma P-tau217 discriminated AD from other neurodegenerative diseases, with significantly higher accuracy than established plasma- and MRI-based biomarkers, and its performance was not significantly different from key CSF- or PET-based measures. Further research is needed to optimize the assay, validate the findings in unselected and diverse populations, and determine its potential role in clinical care.

Topics & Keywords

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Parkinson's Disease Mechanisms and Treatments

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: JAMA

Volume 324, Issue 8, pp. 772-772

DOI: 10.1001/jama.2020.12134

Field-Weighted Citation Impact: 100.39